Learn about the global bi-specific MAbs market through The Business Research Company, which provides information on bi-specific MAbs market size, bi-specific MAbs market drivers and restraints, bi-specific MAbs market players, the COVID-19 impact on the bi-specific MAbs market, and more.

The global bi-specific MAbs market size is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate (CAGR) of 34.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The bispecific monoclonal antibodies market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%.

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bi-specific monoclonal antibodies market over the forecast period.

Request A Sample For The Global Bi-Specific MAbs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.

 Global Bi-Specific MAbs Market Segments Include:

By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597

By Product Type: In Vivo, In Vitro

By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others

By End Use: Hospitals, Research Institutes, Others

By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Companies in the bi-specific MAbs market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company.

TBRC’s bi-specific MAbs market report covers:

Major Market Players: Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott.

Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Time Series: Five years historic (2016-21) and ten years forecast (2022-2026-2031)

The Bi-Specific MAbs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides bi-specific MAbs market overviews, analyses and forecasts market size, share, bi-specific MAbs market players, bi-specific MAbs market segments and geographies, leading competitor revenues, profiles and market shares.

TBRC’s bi-specific MAbs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.

Here Is A List Of Similar Reports From The Business Research Company:

Biologics Global Market Report 2022

Monoclonal Antibodies (MAbS) Global Market Report 2022

Conjugated Monoclonal Antibodies Global Market Report 2022

Interested To Know More About The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info

Found This Article Helpful? Share It On: